Study Assuages Fears of Pancreatic Cancer Risk With GLP-1 Receptor Agonists
Several years after initiating treatment, GLP-1 receptor agonist users didn’t have a pancreatic cancer safety signal, a historical cohort study reported. Compared with basal insulin users, those on a GLP-1 receptor agonist didn’t have a significantly different risk for developing pancreatic cancer in the 5 to 7 years that followed (HR 0.50, 95% CI 0.15-1.71), […]